The Impact of Antibiotic Therapy on Intestinal Microbiota: Dysbiosis, Antibiotic Resistance, and Restoration Strategies
Влияние антибиотикотерапии на кишечную микробиоту: дисбиоз, антибиотикорезистентность и стратегии восстановления
2025-04-03
SCID: 54.1/6htze933
Discuss with AI
antibiotic resistanceantibiotic-induced dysbiosisfecal microbiota transplantationgut microbiotamicrobiota–gut–brain axis
Figures from the paper
Abstract (AI)
The human gut microbiota—an intricate and dynamic ecosystem—plays a pivotal role in metabolic regulation, immune modulation, and the maintenance of intestinal barrier integrity. Although antibiotic therapy is indispensable for managing bacterial infections, it profoundly disrupts gut microbial communities. Such dysbiosis is typified by diminished diversity and shifts in community structure, especially among beneficial bacterial genera (e.g., Bifidobacterium and Eubacterium), and fosters antibiotic-resistant strains and the horizontal transfer of resistance genes. These alterations compromise colonization resistance, increase intestinal permeability, and amplify susceptibility to opportunistic pathogens like Clostridioides difficile. Beyond gastrointestinal disorders, emerging evidence associates dysbiosis with systemic conditions, including chronic inflammation, metabolic syndrome, and neurodegenerative diseases, underscoring the relevance of the microbiota–gut–brain axis. The recovery of pre-existing gut communities post-antibiotic therapy is highly variable, influenced by drug spectrum, dosage, and treatment duration. Innovative interventions—such as fecal microbiota transplantation (FMT), probiotics, synbiotics, and precision microbiome therapeutics—have shown promise in counteracting dysbiosis and mitigating its adverse effects. These therapies align closely with antibiotic stewardship programs aimed at minimizing unnecessary antibiotic use to preserve microbial diversity and curtail the spread of multidrug-resistant organisms. This review emphasizes the pressing need for microbiota-centered strategies to optimize antibiotic administration, promote long-term health resilience, and alleviate the disease burden associated with antibiotic-induced dysbiosis.
Key Findings
1
Antibiotic therapy markedly disrupts gut microbial communities, reducing diversity and altering beneficial genera such as Bifidobacterium and Eubacterium.
2
Antibiotic-induced dysbiosis promotes antibiotic-resistant strains and horizontal transfer of resistance genes while weakening colonization resistance against opportunistic pathogens, including Clostridioides difficile.
3
Fecal microbiota transplantation, probiotics, synbiotics, and precision microbiome therapeutics show promise for restoring microbiota and complementing antibiotic stewardship.
4
Microbiota disruption increases intestinal permeability and is associated with gastrointestinal disease, chronic inflammation, metabolic syndrome, and neurodegenerative conditions.
5
Recovery of pre-existing gut communities after antibiotics varies substantially according to drug spectrum, dosage, and treatment duration.
Research Object
Human gut microbiota under antibiotic therapy
Research Subject
Antibiotic-induced dysbiosis, including changes in microbial diversity and community structure, emergence and transfer of antibiotic resistance, health consequences, and microbiota restoration strategies
Publication Details
Publication Date
2025-04-03
Journal
Publisher
ISSN
Cited by
145
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai4
PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation2018
Interaction between microbiota and immunity in health and disease2020
What is the Healthy Gut Microbiota Composition? A Changing Ecosystem across Age, Environment, Diet, and Diseases2019
Microbiome-Driven Therapeutics: From Gut Health to Precision Medicine2025